Altitude Group PLC

Altitude Group encouraged with integration of AI Mastermind business

AI Mastermind is described as “the largest promotional products distributor organization member group in the United States”

Financial results for 2018 are due 28 May

Altitude Group plc (LON:ALT) told investors it is encouraged by the progress being made following the acquisition of the AI Mastermind announced in January and said that financial results for 2018 will be in-line with market expectations.

The AIM-quoted group is due to release its financial results statement on 28 May.

In January, the company announced the acquisition of Advertising Industry Mastermind and at the same time raised £7mln.

READ: Altitude Group acquires Advertising Industry Mastermind

AI Mastermind is described as “the largest promotional products distributor organization member group in the United States”.

In Wednesday’s statement, Altitude said the integration of the AI Mastermind business has gone well and it is continuing to increase membership and generate revenue through enhanced marketing, technology and sales support.

"The company made substantial progress in 2018 and has developed further in the short period following the acquisition of AI Mastermind and its subsequent rapid, successful integration,” said Nichole Stella, Altitude chief executive.

She added: “We have made good initial progress and are encouraged that both members and supplier partners are recognising our enhanced, combined service.

“We are more convinced than ever about the potential of our model and of the benefits that will be derived following the acquisition of AI Mastermind.

Quick facts: Altitude Group PLC

Price: £1.00

Market: AIM
Market Cap: £68.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

14 hours, 13 minutes ago

2 min read